Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
45 patents granted to the 5 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Plus Therapeutics, Inc.’s names, not what it holds today.
Patents granted
45
45 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
52
1 of them in 2025
Names they are printed under
5
a former name
By yearGrantedApplications published
'08'09'10'11'12'13'14'15'16'17'18'20'22'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
Under which name5 counted
CYTORI THERAPEUTICS, INC. a former name
US, as the owner printed on each patent
27 publishedCYTORI THERAPEUTICS, INC. a former name
named as the applicant on its applications, in US. 1 more under the same name are not counted (printed in JP)
20 publishedMacropore a former name
US, as the owner printed on each patent
1 publishedPlus Therapeutics, Inc. a former name
US, as the owner printed on each patent
3 publishedPlus Therapeutics, Inc. a former name
named as the applicant on its applications, in US
1 publishedNames not counted (1)
CYTORI THERAPEUTICS, INC.
Most of its patents print JP; this name counts in US. 0 granted and 1 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Nov 6, 2018 | 10,119,113 | Systems for isolating and using clinically safe adipose derived regenerative cells | Biotechnology | CYTORI THERAPEUTICS, INC. |
| Jan 23, 2018 | 9,872,877 | Methods of using regenerative cells to promote epithelialization or neodermis formation | Pharmaceuticals | CYTORI THERAPEUTICS, INC. |
| Dec 26, 2017 | 9,849,149 | Methods of using regenerative cells in the treatment of erectile dysfunction | Pharmaceuticals | CYTORI THERAPEUTICS, INC. |
| Mar 21, 2017 | 9,597,395 | Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions | Pharmaceuticals | CYTORI THERAPEUTICS, INC. |
| Dec 6, 2016 | 9,511,096 | Methods of using regenerative cells to treat an ischemic wound | Pharmaceuticals | CYTORI THERAPEUTICS, INC. |
| Dec 6, 2016 | 9,511,094 | Methods of using regenerative cells in the treatment of stroke and related diseases and disorders | Pharmaceuticals | CYTORI THERAPEUTICS, INC. |
| Nov 29, 2016 | 9,504,718 | Methods of using adipose derived regenerative cells in the treatment of renal diseases and disorders | Medical technology | CYTORI THERAPEUTICS, INC. |
| Nov 29, 2016 | 9,504,716 | Methods of using adipose derived regenerative cells to promote restoration of intevertebral disc | Medical technology | CYTORI THERAPEUTICS, INC. |
| Nov 15, 2016 | 9,492,483 | Methods of using regenerative cells to treat a burn | Pharmaceuticals | CYTORI THERAPEUTICS, INC. |
| Nov 8, 2016 | 9,486,484 | Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease | Pharmaceuticals | CYTORI THERAPEUTICS, INC. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 23, 2025 | 2025/0325715 | RADIOLABELED LIPOSOMES AND METHODS OF USE FOR TREATING LEPTOMENINGEAL METASTASES | Pharmaceuticals | Plus Therapeutics, Inc. |
| Jun 20, 2024 | 2024/0197932 | Biodegradable Alginate Microspheres | Pharmaceuticals | Plus Therapeutics, Inc. |
| Sep 1, 2022 | 2022/0273832 | RADIOLABELED LIPOSOMES AND METHODS OF USE THEREOF | Pharmaceuticals | Plus Therapeutics, Inc. |
| Dec 17, 2020 | 2020/0390702 | LIPOSOMAL TAXANES FOR TREATMENT OF SCLC | Pharmaceuticals | Plus Therapeutics, Inc. |
| Oct 19, 2017 | 2017/0296697 | USE OF REGENERATIVE CELLS IN MITIGATING BURN PROGRESSION AND IMPROVING SKIN GRAFT INCORPORATION AND HEALING | Medical technology | CYTORI THERAPEUTICS, INC. |
| Oct 5, 2017 | 2017/0281771 | METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS | Pharmaceuticals | CYTORI THERAPEUTICS, INC. |
| Jul 20, 2017 | 2017/0205322 | CENTRIFUGE CHAMBER | Biotechnology | CYTORI THERAPEUTICS, INC. |
| May 18, 2017 | 2017/0136069 | CELL CARRIER AND CELL CARRIER CONTAINMENT DEVICES CONTAINING REGENERATIVE CELLS | Medical technology | CYTORI THERAPEUTICS, INC. |
| May 18, 2017 | 2017/0136067 | METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS | Medical technology | CYTORI THERAPEUTICS, INC. |
| May 18, 2017 | 2017/0136066 | METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF RENAL DISEASES AND DISORDERS | Medical technology | CYTORI THERAPEUTICS, INC. |
What it applied for, 2024 to 2025: Pharmaceuticals 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.